Q2-osavuosiraportti
87 päivää sitten‧45 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
211 778
Myynti
Määrä
16 819
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 041 | - | - | ||
| 1 108 | - | - | ||
| 418 | - | - | ||
| 513 | - | - | ||
| 7 961 | - | - |
Ylin
0,29VWAP
Alin
0,258VaihtoMäärä
2,4 8 874 509
VWAP
Ylin
0,29Alin
0,258VaihtoMäärä
2,4 8 874 509
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sitten · MuokattuThe trading volume today is somewhat better than the days before. And on a Friday, no less. Are there opportunities before Q3? As well as, of course, what everyone is waiting for, a good Q3, or something like that? Where is the bottleneck at the moment? And which way will this flow when it loosens? 🙈🤤
·2 päivää sittenWe really need some positive news...·2 päivää sitten · MuokattuMust the news be fresh? We have actually had some news during the emission. Q3 (quarterly figures) is coming. The stock rose somewhat yesterday just on the invitation to the webcast/telefoncast. No one without a leak can know for sure what will be said during the Q3 presentation. It can go in all directions from then. Stock price has "binary nature" then (up/down, equally far or further/shorter).·2 päivää sitten · MuokattuMy reflections: But it should be factored in that day, the price "repairs itself". If not, one is not keeping up with the times. I understand that it is not possible during the emission. But now it is over. So the share with the dilution is without news perhaps worth close to just under 50 öre. Then you naturally have the negativity amplification of the dilution itself. Is it supposed to be like that, that the positive drowns? One can also ask oneself if the share before PancreaSure-launch happened was over-hyped, or about how it will be further on news. The emission coincided with the launch. Management must have thought that it was better "to pull the plaster off the wound", when there is some positivity? But they were probably more realistic and knew that they needed capital to achieve the launch and a proper development. The dilution figure is at least known. I think it was 52,2 %. After that, we know the price before which hovered around 90/96 öre. Then we have had various events since which makes it more difficult to relate to. We will probably never get a completely accurate calculation of value, or will we? Before profit gives fixed frameworks to relate to. Profit is tangible figures per quarter. Also, development signals will make the share price run ahead of profit/loss (always), whether they are good or bad signals. One can in that sense, for example, have everything from layoffs to new contract signings to mention some possibilities in a company's development. Before the emission with over-hyping, the share was in good momentum to pass 1 krone. I believe that it would have continued a good way into over 1 krone-territory. 1 krone may have been a barrier, but often when the technical analytical passes resistance levels, it gives further upside. Something like that can happen again. Hopefully news-driven this time, in contrast to hyping.
·19.11.Said it before, saying it again, these low trading volumes make the stock volatile. Short selling is almost down to zero, however, that signals that one does not believe in a significantly lower price. Based on the price, it is unfortunately at the bottom, but I personally continue to have confidence that the company can turn this sharply upwards once launches are completed and cash starts flowing into the company. When the bottleneck disappears, it will likely rise very quickly and that will attract larger investors when the company can show good figures.·3 päivää sittenAs mentioned, larger investors are needed who believe in the company's ability to the extent that one is prepared to invest large sums. Otherwise, another company will probably buy up the company because the product is world-class.·3 päivää sitten · MuokattuBut it's a zero-sum game. Fewer small investors contributed the money in the emission now. That's when the capital injection happened. Ordinary stock trading adds approximately null kroner to Immunovia AB, unless they are active in the trading themselves. Some complained that management didn't buy enough, I seem to recall. But they also participated a bit in the capital raising. Large players contribute absolutely null to the zero-sum game. They can contribute to more liquid trading. I think the stagnation is due to the emission (aftermath). It's starting to ripple more again on good news, not so much on how big an investor is holding on. For example, you would have found it boring if Warren Buffett bought into this stock. Because he comes with a huge purchase and then holds his position, only for it to become equally dead again. The only thing it would have led to is more activity in trading over the small transactions he had spread his million-purchase over. The only thing that would have happened is that someone would have nearly sold out to him.. i.e., the zero-sum game. It would not have given a lasting boost. The stock price would have settled into its normal pattern anyway, given time.
·19.11.Immunovia, We look forward to the next new share issue, it probably won't be long now. You (Immunovia) can perhaps learn from your colleagues in Lund, Hansa Biopharma. They know how to rig the price before raising new money. New share issue at 39.50 kronor in September, now the share is paid at 26 kronor.
·18.11.Outlook and Risks Immunovia has a high short interest, which increases volatility and the risk level. Several financial sites and analyses assess that the company's future strongly depends on successful product launch and capital raising in 2025; should these fail, the risk of further price decline is high. Technical indicators such as RSI are near 39, which signals a weak buy opportunity, but the low price relative to moving averages still indicates a negative trend. Immunovia's innovative cancer diagnostics has potential, but the market is hesitant until the company shows growth and reduced loss. Conclusion The outlook for the Immunovia share remains uncertain with a risk of further price decline unless the company manages to reverse the trend and raise new capital in 2025. The low share price and negative results make the stock very risky, but if the company succeeds with product launch and financing, there is a possibility of recovery.·19.11.Larger investors might be entering the market in the near term. If that becomes reality, we know that the price will shoot up quickly and significantly.·19.11. · MuokattuIt's possible that it's positive if it's of the long-term type. At the same time, you will get new large players on the scene who, through their trading, can start to dictate the stock price to a certain extent at least. We already have owners of the shares that exist. That's not where the problem lies long-term. Of course, they could create a bit more movement in the market. But a crowd of small investors can also provide that, if there is company development to reward. I am not over-optimistic that the larger players absolutely must own. The Pension Fund (oil) and similar would not have hurt. Meaning, someone who injects some new funds. But eventually they will trigger too large ownership and trigger an acquisition. It's too early for an acquisition now, I think. Shouldn't we wish to share the opportunities with more people, quite a long time before such a thing becomes relevant? So that one gets some growth for all of us, so that when such a day comes, you will have something to diversify your portfolio with?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
87 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuThe trading volume today is somewhat better than the days before. And on a Friday, no less. Are there opportunities before Q3? As well as, of course, what everyone is waiting for, a good Q3, or something like that? Where is the bottleneck at the moment? And which way will this flow when it loosens? 🙈🤤
- ·2 päivää sittenWe really need some positive news...·2 päivää sitten · MuokattuMust the news be fresh? We have actually had some news during the emission. Q3 (quarterly figures) is coming. The stock rose somewhat yesterday just on the invitation to the webcast/telefoncast. No one without a leak can know for sure what will be said during the Q3 presentation. It can go in all directions from then. Stock price has "binary nature" then (up/down, equally far or further/shorter).·2 päivää sitten · MuokattuMy reflections: But it should be factored in that day, the price "repairs itself". If not, one is not keeping up with the times. I understand that it is not possible during the emission. But now it is over. So the share with the dilution is without news perhaps worth close to just under 50 öre. Then you naturally have the negativity amplification of the dilution itself. Is it supposed to be like that, that the positive drowns? One can also ask oneself if the share before PancreaSure-launch happened was over-hyped, or about how it will be further on news. The emission coincided with the launch. Management must have thought that it was better "to pull the plaster off the wound", when there is some positivity? But they were probably more realistic and knew that they needed capital to achieve the launch and a proper development. The dilution figure is at least known. I think it was 52,2 %. After that, we know the price before which hovered around 90/96 öre. Then we have had various events since which makes it more difficult to relate to. We will probably never get a completely accurate calculation of value, or will we? Before profit gives fixed frameworks to relate to. Profit is tangible figures per quarter. Also, development signals will make the share price run ahead of profit/loss (always), whether they are good or bad signals. One can in that sense, for example, have everything from layoffs to new contract signings to mention some possibilities in a company's development. Before the emission with over-hyping, the share was in good momentum to pass 1 krone. I believe that it would have continued a good way into over 1 krone-territory. 1 krone may have been a barrier, but often when the technical analytical passes resistance levels, it gives further upside. Something like that can happen again. Hopefully news-driven this time, in contrast to hyping.
- ·19.11.Said it before, saying it again, these low trading volumes make the stock volatile. Short selling is almost down to zero, however, that signals that one does not believe in a significantly lower price. Based on the price, it is unfortunately at the bottom, but I personally continue to have confidence that the company can turn this sharply upwards once launches are completed and cash starts flowing into the company. When the bottleneck disappears, it will likely rise very quickly and that will attract larger investors when the company can show good figures.·3 päivää sittenAs mentioned, larger investors are needed who believe in the company's ability to the extent that one is prepared to invest large sums. Otherwise, another company will probably buy up the company because the product is world-class.·3 päivää sitten · MuokattuBut it's a zero-sum game. Fewer small investors contributed the money in the emission now. That's when the capital injection happened. Ordinary stock trading adds approximately null kroner to Immunovia AB, unless they are active in the trading themselves. Some complained that management didn't buy enough, I seem to recall. But they also participated a bit in the capital raising. Large players contribute absolutely null to the zero-sum game. They can contribute to more liquid trading. I think the stagnation is due to the emission (aftermath). It's starting to ripple more again on good news, not so much on how big an investor is holding on. For example, you would have found it boring if Warren Buffett bought into this stock. Because he comes with a huge purchase and then holds his position, only for it to become equally dead again. The only thing it would have led to is more activity in trading over the small transactions he had spread his million-purchase over. The only thing that would have happened is that someone would have nearly sold out to him.. i.e., the zero-sum game. It would not have given a lasting boost. The stock price would have settled into its normal pattern anyway, given time.
- ·19.11.Immunovia, We look forward to the next new share issue, it probably won't be long now. You (Immunovia) can perhaps learn from your colleagues in Lund, Hansa Biopharma. They know how to rig the price before raising new money. New share issue at 39.50 kronor in September, now the share is paid at 26 kronor.
- ·18.11.Outlook and Risks Immunovia has a high short interest, which increases volatility and the risk level. Several financial sites and analyses assess that the company's future strongly depends on successful product launch and capital raising in 2025; should these fail, the risk of further price decline is high. Technical indicators such as RSI are near 39, which signals a weak buy opportunity, but the low price relative to moving averages still indicates a negative trend. Immunovia's innovative cancer diagnostics has potential, but the market is hesitant until the company shows growth and reduced loss. Conclusion The outlook for the Immunovia share remains uncertain with a risk of further price decline unless the company manages to reverse the trend and raise new capital in 2025. The low share price and negative results make the stock very risky, but if the company succeeds with product launch and financing, there is a possibility of recovery.·19.11.Larger investors might be entering the market in the near term. If that becomes reality, we know that the price will shoot up quickly and significantly.·19.11. · MuokattuIt's possible that it's positive if it's of the long-term type. At the same time, you will get new large players on the scene who, through their trading, can start to dictate the stock price to a certain extent at least. We already have owners of the shares that exist. That's not where the problem lies long-term. Of course, they could create a bit more movement in the market. But a crowd of small investors can also provide that, if there is company development to reward. I am not over-optimistic that the larger players absolutely must own. The Pension Fund (oil) and similar would not have hurt. Meaning, someone who injects some new funds. But eventually they will trigger too large ownership and trigger an acquisition. It's too early for an acquisition now, I think. Shouldn't we wish to share the opportunities with more people, quite a long time before such a thing becomes relevant? So that one gets some growth for all of us, so that when such a day comes, you will have something to diversify your portfolio with?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
211 778
Myynti
Määrä
16 819
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 041 | - | - | ||
| 1 108 | - | - | ||
| 418 | - | - | ||
| 513 | - | - | ||
| 7 961 | - | - |
Ylin
0,29VWAP
Alin
0,258VaihtoMäärä
2,4 8 874 509
VWAP
Ylin
0,29Alin
0,258VaihtoMäärä
2,4 8 874 509
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
87 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 26.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Merkintäoikeusanti | 2.10. | |
| 2025 Ylimääräinen yhtiökokous | 29.9. | |
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Yhtiökokous | 14.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten · MuokattuThe trading volume today is somewhat better than the days before. And on a Friday, no less. Are there opportunities before Q3? As well as, of course, what everyone is waiting for, a good Q3, or something like that? Where is the bottleneck at the moment? And which way will this flow when it loosens? 🙈🤤
- ·2 päivää sittenWe really need some positive news...·2 päivää sitten · MuokattuMust the news be fresh? We have actually had some news during the emission. Q3 (quarterly figures) is coming. The stock rose somewhat yesterday just on the invitation to the webcast/telefoncast. No one without a leak can know for sure what will be said during the Q3 presentation. It can go in all directions from then. Stock price has "binary nature" then (up/down, equally far or further/shorter).·2 päivää sitten · MuokattuMy reflections: But it should be factored in that day, the price "repairs itself". If not, one is not keeping up with the times. I understand that it is not possible during the emission. But now it is over. So the share with the dilution is without news perhaps worth close to just under 50 öre. Then you naturally have the negativity amplification of the dilution itself. Is it supposed to be like that, that the positive drowns? One can also ask oneself if the share before PancreaSure-launch happened was over-hyped, or about how it will be further on news. The emission coincided with the launch. Management must have thought that it was better "to pull the plaster off the wound", when there is some positivity? But they were probably more realistic and knew that they needed capital to achieve the launch and a proper development. The dilution figure is at least known. I think it was 52,2 %. After that, we know the price before which hovered around 90/96 öre. Then we have had various events since which makes it more difficult to relate to. We will probably never get a completely accurate calculation of value, or will we? Before profit gives fixed frameworks to relate to. Profit is tangible figures per quarter. Also, development signals will make the share price run ahead of profit/loss (always), whether they are good or bad signals. One can in that sense, for example, have everything from layoffs to new contract signings to mention some possibilities in a company's development. Before the emission with over-hyping, the share was in good momentum to pass 1 krone. I believe that it would have continued a good way into over 1 krone-territory. 1 krone may have been a barrier, but often when the technical analytical passes resistance levels, it gives further upside. Something like that can happen again. Hopefully news-driven this time, in contrast to hyping.
- ·19.11.Said it before, saying it again, these low trading volumes make the stock volatile. Short selling is almost down to zero, however, that signals that one does not believe in a significantly lower price. Based on the price, it is unfortunately at the bottom, but I personally continue to have confidence that the company can turn this sharply upwards once launches are completed and cash starts flowing into the company. When the bottleneck disappears, it will likely rise very quickly and that will attract larger investors when the company can show good figures.·3 päivää sittenAs mentioned, larger investors are needed who believe in the company's ability to the extent that one is prepared to invest large sums. Otherwise, another company will probably buy up the company because the product is world-class.·3 päivää sitten · MuokattuBut it's a zero-sum game. Fewer small investors contributed the money in the emission now. That's when the capital injection happened. Ordinary stock trading adds approximately null kroner to Immunovia AB, unless they are active in the trading themselves. Some complained that management didn't buy enough, I seem to recall. But they also participated a bit in the capital raising. Large players contribute absolutely null to the zero-sum game. They can contribute to more liquid trading. I think the stagnation is due to the emission (aftermath). It's starting to ripple more again on good news, not so much on how big an investor is holding on. For example, you would have found it boring if Warren Buffett bought into this stock. Because he comes with a huge purchase and then holds his position, only for it to become equally dead again. The only thing it would have led to is more activity in trading over the small transactions he had spread his million-purchase over. The only thing that would have happened is that someone would have nearly sold out to him.. i.e., the zero-sum game. It would not have given a lasting boost. The stock price would have settled into its normal pattern anyway, given time.
- ·19.11.Immunovia, We look forward to the next new share issue, it probably won't be long now. You (Immunovia) can perhaps learn from your colleagues in Lund, Hansa Biopharma. They know how to rig the price before raising new money. New share issue at 39.50 kronor in September, now the share is paid at 26 kronor.
- ·18.11.Outlook and Risks Immunovia has a high short interest, which increases volatility and the risk level. Several financial sites and analyses assess that the company's future strongly depends on successful product launch and capital raising in 2025; should these fail, the risk of further price decline is high. Technical indicators such as RSI are near 39, which signals a weak buy opportunity, but the low price relative to moving averages still indicates a negative trend. Immunovia's innovative cancer diagnostics has potential, but the market is hesitant until the company shows growth and reduced loss. Conclusion The outlook for the Immunovia share remains uncertain with a risk of further price decline unless the company manages to reverse the trend and raise new capital in 2025. The low share price and negative results make the stock very risky, but if the company succeeds with product launch and financing, there is a possibility of recovery.·19.11.Larger investors might be entering the market in the near term. If that becomes reality, we know that the price will shoot up quickly and significantly.·19.11. · MuokattuIt's possible that it's positive if it's of the long-term type. At the same time, you will get new large players on the scene who, through their trading, can start to dictate the stock price to a certain extent at least. We already have owners of the shares that exist. That's not where the problem lies long-term. Of course, they could create a bit more movement in the market. But a crowd of small investors can also provide that, if there is company development to reward. I am not over-optimistic that the larger players absolutely must own. The Pension Fund (oil) and similar would not have hurt. Meaning, someone who injects some new funds. But eventually they will trigger too large ownership and trigger an acquisition. It's too early for an acquisition now, I think. Shouldn't we wish to share the opportunities with more people, quite a long time before such a thing becomes relevant? So that one gets some growth for all of us, so that when such a day comes, you will have something to diversify your portfolio with?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
211 778
Myynti
Määrä
16 819
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 041 | - | - | ||
| 1 108 | - | - | ||
| 418 | - | - | ||
| 513 | - | - | ||
| 7 961 | - | - |
Ylin
0,29VWAP
Alin
0,258VaihtoMäärä
2,4 8 874 509
VWAP
Ylin
0,29Alin
0,258VaihtoMäärä
2,4 8 874 509
Välittäjätilasto
Dataa ei löytynyt